BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35507606)

  • 1. Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study.
    Elmekaty EZI; Alibrahim R; Hassanin R; Eltaib S; Elsayed A; Rustom F; Mohamed Ibrahim MI; Abu Khattab M; Al Soub H; Al Maslamani M; Al-Khal A
    PLoS One; 2022; 17(5):e0267884. PubMed ID: 35507606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
    Lai CC; Chao CM; Hsueh PR
    J Microbiol Immunol Infect; 2021 Oct; 54(5):767-775. PubMed ID: 34253490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
    Meriglier E; Rivoisy C; Hessamfar M; Bernard N; Aureau I; Lapoirie J; Contis A; Sacher F; Sacristan B; Lahouati M; Pedeboscq S; Vandenhende MA; Bouchet S; Bonnet F
    J Antimicrob Chemother; 2021 Jan; 76(2):482-486. PubMed ID: 33221868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
    Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
    Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis.
    Bhattacharyya A; Kumar S; Sarma P; Kaur H; Prajapat M; Shekhar N; Bansal S; Avti P; Hazarika M; Sharma S; Mahendru D; Prakash A; Medhi B
    Indian J Pharmacol; 2020; 52(4):313-323. PubMed ID: 33078733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
    Yunquera-Romero L; Asensi-Díez R; Del Rio-Valencia JC; Muñoz-Castillo I; Castaño-Carracedo MA
    Rev Esp Quimioter; 2016 Dec; 29(6):308-317. PubMed ID: 27888600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
    Madruga JV; Berger D; McMurchie M; Suter F; Banhegyi D; Ruxrungtham K; Norris D; Lefebvre E; de Béthune MP; Tomaka F; De Pauw M; Vangeneugden T; Spinosa-Guzman S;
    Lancet; 2007 Jul; 370(9581):49-58. PubMed ID: 17617272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
    Inciarte A; Leal L; González E; León A; Lucero C; Mallolas J; Torres B; Laguno M; Rojas J; Martínez-Rebollar M; González-Cordón A; Cruceta A; Arnaiz JA; Gatell JM; García F;
    J Antimicrob Chemother; 2017 Oct; 72(10):2857-2861. PubMed ID: 29091217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.
    Venter WDF; Moorhouse M; Sokhela S; Serenata C; Akpomiemie G; Qavi A; Mashabane N; Arulappan N; Sim JW; Sinxadi PZ; Wiesner L; Maharaj E; Wallis C; Boyles T; Ripin D; Stacey S; Chitauri G; Hill A
    Lancet HIV; 2019 Jul; 6(7):e428-e437. PubMed ID: 31202690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
    Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology, diagnosis and treatment of early COVID-19 patients in Jiaxing City, Zhejiang Province, China, January to March 2020.
    Lin J; Shen P; Zhang Y; Lv X; Deng M; Shen L; Chen W
    Ann Palliat Med; 2022 Nov; 11(11):3472-3482. PubMed ID: 36464971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial.
    Shi N; Guo L; Liu B; Bian Y; Chen R; Chen S; Chen Y; Chen Y; Cong X; Dong G; Guo J; Hu L; Jiang J; Leng L; Li B; Li D; Li H; Li J; Li L; Liu J; Lu C; Lv W; Miao Q; Qi W; Shi Z; Shi J; Shi H; Tian Y; Wang B; Wang G; Wang J; Wang W; Xian Y; Xie X; Xiong Y; Xu C; Xu M; Yan B; Yang J; Zhang L; Zhou Z; Zhu H; Huang L
    Phytomedicine; 2021 Jan; 81():153367. PubMed ID: 33260064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
    Bartels H; Decosterd L; Battegay M; Marzolini C
    J Antimicrob Chemother; 2017 Sep; 72(9):2574-2577. PubMed ID: 28575323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
    Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dual role of anti-viral therapy in the treatment of Coronavirus disease 2019.
    Liu JY; Hua MX; Du CJ; Pu L; Xiang P; Li CS; Xiong HF; Liu XZ; Chen ZH; Xie W; Li A
    Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11939-11944. PubMed ID: 33275267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monotherapy with boosted PIs as an ART simplification strategy in clinical practice.
    Santos JR; Llibre JM; Berrio-Galan D; Bravo I; Miranda C; Pérez-Alvarez S; Pérez-Alvarez N; Paredes R; Clotet B; Moltó J
    J Antimicrob Chemother; 2015 Apr; 70(4):1124-9. PubMed ID: 25525196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia.
    Milic J; Novella A; Meschiari M; Menozzi M; Santoro A; Bedini A; Cuomo G; Franceschini E; Digaetano M; Carli F; Ciusa G; Volpi S; Bacca E; Franceschi G; Yaacoub D; Rogati C; Tutone M; Burastero G; Faltoni M; Iadisernia V; Dolci G; Cossarizza A; Mussini C; Pasina L; Guaraldi G
    AIDS Res Hum Retroviruses; 2021 Apr; 37(4):283-291. PubMed ID: 33619997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.
    Nelson M; Girard PM; Demasi R; Chen L; Smets E; Sekar V; Lavreys L
    J Antimicrob Chemother; 2010 Jul; 65(7):1505-9. PubMed ID: 20498120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Streptococcus Pneumoniae Urinary Antigen Testing in Decreasing Mortality of COVID-19 Co-Infected Patients: A Clinical Investigation.
    Desai A; Santonocito OG; Caltagirone G; Kogan M; Ghetti F; Donadoni I; Porro F; Savevski V; Poretti D; Ciccarelli M; Martinelli Boneschi F; Voza A
    Medicina (Kaunas); 2020 Oct; 56(11):. PubMed ID: 33138045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.